Stifel analyst Benjamin Burnett reiterated a Buy rating and $92.00 price target on Global Blood Therapeutics (NASDAQ: GBT) after commissioning ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE